Skip to content

Vibrotactile Coordinated Reset for the Treatment of Chronic Stroke

Vibrotactile Coordinated Reset for the Treatment of Chronic Stroke

Status
Not yet recruiting
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT05490277
Enrollment
20
Registered
2022-08-05
Start date
2026-01-15
Completion date
2028-11-15
Last updated
2025-05-15

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Chronic Stroke

Brief summary

The purpose of our study is to evaluate Vibrotactile Coordinated Reset stimulation (vCR) and its effects on motor ability within stroke patients. vCR will be administered with a device called the Vibrotactile (VT) Brain Glove. vCR is expected to provide patients with a non-invasive therapy to aid in recovery from a stroke. This study will include a dedicated sham arm that will aid in understanding true treatment effects from vCR.

Interventions

Participants will receive active vibrotactile coordinated reset (vCR) which sends gentle vibrations to the fingertips at a specific pattern. The purpose of the intervention is to test the efficacy of active vCR in comparison to sham vCR.

Participants will receive sham vibrotactile coordinated reset (vCR) which sends gentle vibrations to the fingertips at a specific pattern. The purpose of the intervention is to test the efficacy of active vCR in comparison to sham vCR.

Sponsors

Stanford University
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
CROSSOVER
Primary purpose
TREATMENT
Masking
QUADRUPLE (Subject, Caregiver, Investigator, Outcomes Assessor)

Eligibility

Sex/Gender
ALL
Age
18 Years to 80 Years
Healthy volunteers
No

Inclusion criteria

1. Age at the time of enrollment: 18-80 years 2. Diagnosis of ischemic or hemorrhagic stroke 3. Disease period of more than 6 months 4. Mini Mental State Examination of at least 24 points 5. No medications that affect balance 6. Motor deficit 7. Use of Motricity Arm and Leg index to include impaired individuals with some functioning 8. Modified Rankin Scale for Neurologic Disability: Scores 3 or 4

Exclusion criteria

1. Any significant psychiatric problems, including acute confusional state (delirium), ongoing psychosis, or clinically significant depression 2. Any current drug or alcohol abuse 3. History of recurrent or unprovoked seizures 4. Any neurological disorder treatments that involve intracranial surgery or device implantation 5. Participation in another drug, device or biologic trial concurrently or within the preceding days 6. Pregnancy, breastfeeding or wanting to become pregnant during the trial 7. History or presence of other major neurological or orthopedic diseases other than stroke that limits motor functioning or cognitive ability 8. More than 5 degrees of contracture at shoulder, elbow, wrist, finger, hip, knee, or ankle 9. Botox, baclofen or any other treatment for spasticity except for bracing or splinting within the previous 3 months 10. Must be able to communicate with staff 11. Severe sensory abnormalities of the fingers such as vibratory urticaria

Design outcomes

Primary

MeasureTime frameDescription
Fugl Meyer Assessment of Motor Recovery after Stroke change from baseline, 3 months, 4 months, 7months and 8 monthsThis clinical assessment will be done at baseline visit, three month visit, four month visit, seven month visit and eight month visitThe Fugl-Meyer Assessment (FMA) is a stroke-specific, performance-based impairment index. It is designed to assess motor functioning, balance, sensation and joint functioning in patients with post-stroke hemiplegia. It is applied clinically and in research to determine disease severity, describe motor recovery, and to plan and assess treatment. The scale is comprised of five domains and there are 155 items in total. Scoring is based on direct observation of performance. Scale items are scored on the basis of ability to complete the item using a 3-point ordinal scale where 0=cannot perform, 1=performs partially and 2=performs fully. The total possible scale score is 226.
Neuro Quality of Life Upper Extremity Short Form test change from baseline, 3 months, 4 months, 7months and 8 monthsThis clinical assessment will be done at baseline visit, three month visit, four month visit, seven month visit and eight month visitThe Neuro quality of life upper extremity short form test measures the functionality of upper extremities. This is a self-report questionnaire that has a Likert scale from 1 to 5, with 5 indicating no difficulties and 1 indicating unable to do. Total possible points are out of 40, with a higher score indicating better upper extremity abilities.

Secondary

MeasureTime frameDescription
Timed Up and Go test change from baseline, 3 months, 4 months, 7months and 8 monthsThis clinical assessment will be done at baseline visit, three month visit, four month visit, seven month visit and eight month visitThis test is a measure walking ability with correlates to balance and fall risk. The patient is timed using a stopwatch and the patient is instructed to walk as quickly as possible for 3 meters. The test is scored as such: ≤ 10 seconds = normal ≤ 20 seconds = good mobility, can go out alone, mobile without gait aid ≤ 30 seconds = problems, cannot go outside alone, requires gait aid \* A score of ≥ 14 seconds has been shown to indicate high risk of falls
Neuro Quality of Life Lower Extremity Short Form test change from baseline, 3 months, 4 months, 7months and 8 monthsThis clinical assessment will be done at baseline visit, three month visit, four month visit, seven month visit and eight month visitThe Neuro quality of life lower extremity short form test measures the functionality of upper extremities. This is a self-report questionnaire that has a Likert scale from 1 to 5, with 5 indicating no difficulties and 1 indicating unable to do. Total possible points are out of 40, with a higher score indicating better lower extremity abilities.
Barthel Index for Activities of Daily Living change from baseline, 3 months, 4 months, 7months and 8 monthsThis clinical assessment will be done at baseline visit, three month visit, four month visit, seven month visit and eight month visitThe Barthel Index (BI) measures the extent to which somebody can function independently and has mobility in their activities of daily living (ADL) i.e. feeding, bathing, grooming, dressing, bowel control, bladder control, toileting, chair transfer, ambulation and stair climbing. Functional categories may be scored from 0 to 1, 0 to 2, or 0 to 3, depending on the item. Total scores range from 0 to 20, with lower scores indicating increased disability
Vibratory temporal discrimination taskThis clinical assessment will be done at baseline visit, three month visit, four month visit, seven month visit and eight month visitPatients receive vibratory stimuli on two fingers either simultaneously or at different times and indicate the perceived timing by pressing a button.
Sensorimotor reaction time taskThis clinical assessment will be done at baseline visit, three month visit, four month visit, seven month visit and eight month visitPatients receive vibratory stimuli on a finger and indicate when stimuli are felt by pressing a button.
Action Research Arm Test change from baseline, 3 months, 4 months, 7months and 8 monthsThis clinical assessment will be done at baseline visit, three month visit, four month visit, seven month visit and eight month visitThe Action Research Arm Test (ARAT) is a 19 item observational measure used by physical therapists and other health care professionals to assess upper extremity performance (coordination, dexterity and functioning) in stroke recovery, brain injury and multiple sclerosis populations.Items comprising the ARAT are categorized into four subscales (grasp, grip, pinch and gross movement). Task performance is rated on a 4-point scale, ranging from 0 (no movement) to 3 (movement performed normally). Scores on the ARAT may range from 0-57 points, with a maximum score of 57 points indicating better performance.

Countries

United States

Contacts

Primary ContactJessica Yankulova
jessky@stanford.edu650-474-9547

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026